Wells Fargo initiates Milestone Pharmaceuticals stock with Overweight rating

Wells Fargo initiated coverage on Milestone Pharmaceuticals (MIST) with an Overweight rating and a $4.00 price target, citing the potential of its nasal-administered Etripamil (CARDAMYST) for paroxysmal supraventricular tachycardia (PSVT), supported by strong Phase 3 results and a differentiated delivery method. This positive outlook comes despite a recent stock decline following a $52.5 million public offering at $1.50 per share and ongoing FDA review for CARDAMYST, which has a December 13, 2025 action date after resubmission to address Chemistry, Manufacturing, and Controls issues. While the company is burning cash, its strong liquidity position provides a cushion for development and commercial preparedness, positioning it for a potentially significant market entry pending regulatory approval.

Analysis

Wells Fargo has initiated coverage on Milestone Pharmaceuticals (MIST) with an Overweight rating and a $4.00 price target, representing significant potential upside from its current $1.71 trading price. The positive outlook is centered on the company's lead drug candidate, Etripamil (CARDAMYST), a nasal-administered treatment for paroxysmal supraventricular tachycardia (PSVT). The drug's differentiation is supported by strong Phase 3 RAPID trial data, which showed a 64% conversion to normal heart rate versus 31% for placebo, and its potential for at-home self-administration could disrupt the current standard of care. However, this speculative opportunity is balanced by considerable risks. The company is characterized by a high cash burn rate, and a recent dilutive public offering of $52.5 million priced at $1.50 per share has already pressured the stock. The most significant hurdle is regulatory, with a distant FDA action date of December 13, 2025, following a resubmission to address Chemistry, Manufacturing, and Controls (CMC) issues from a prior Complete Response Letter. While a strong liquidity position, indicated by a current ratio of 4.97 and an extended $75 million royalty agreement, provides a financial cushion, the investment thesis remains heavily dependent on a binary regulatory outcome over a year away.

Key Decisions for Investors

• For investors with a high risk tolerance, MIST presents a long-term speculative opportunity based on the binary outcome of the FDA's decision on CARDAMYST; the Wells Fargo price target of $4.00 highlights the potential upside if regulatory approval is secured.
• Monitor key upcoming catalysts closely, particularly the company's quarterly cash burn rate against its liquidity and any interim updates from the FDA ahead of the December 13, 2025 action date.
• Consider the recent $1.50 public offering price as a near-term valuation anchor and be mindful of the potential for further share dilution to fund operations leading up to the potential commercial launch.